Paul later said, we have no execution risk as our dose ranging study was conducted under phase 3 trial conditions, and we handled it perfectly well….. The point is, our risk (as we all see it) is finances. But clues in this murder mystery point to a partnership in non binding stage awaiting IND acceptance
-
- There are more pages in this discussion • 835 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $112.9M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 29.5¢ | 28.0¢ | $124.5K | 435.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13421 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 13706 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |